摘要
Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment.Reporting in this issue of Cell,Xiang et al.developed a high-affinity positron emission tomography tracer for alpha-synuclein.
出处
《四川生理科学杂志》
2023年第8期1457-1457,共1页
Sichuan Journal of Physiological Sciences